Equity

Total equity as of September 30, 2015 decreased $247.1 million compared to December 31, 2014. Significant changes were as follows:


•	Additional paid in capital was reduced by share repurchases of $2,998.2 million, as described below, and activity under our share-based compensation arrangements totaling $144.4 million;


•	Other comprehensive losses of $97.9 million; and


•	Net income attributable to Biogen Inc. of $2,715.4 million.

Share Repurchases

In May 2015, our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2015 Share Repurchase Program). This authorization does not have an expiration date. Repurchased shares will be retired. The 2015 Share Repurchase Program is in addition to the approximately 1.3 million shares remaining under our February 2011 Share Repurchase Program (2011 Share Repurchase Program), which has been used principally to offset common stock issuances under our share-based compensation plans.

During the nine months ended September 30, 2015, we repurchased and retired approximately 9.7 million shares of common stock at a cost of $2,998.2 million under our 2015 Share Repurchase Program, which had the effect of reducing additional paid in capital by a similar amount. We did not repurchase any shares of common stock under our 2011 Share Repurchase Program. During the nine months ended September 30, 2014, we purchased approximately 1.2 million shares of common stock at a cost of $360.0 million under our 2011 Share Repurchase Program. As of September 30, 2015, additional paid in capital totaled approximately $1,342.4 million.

Noncontrolling Interests

The following table reconciles equity attributable to noncontrolling interests (NCI):



	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
(In millions)	2015			2014			2015			2014
NCI, beginning of period	$	0.4		$	3.9		$	5.0		$	0.6
Net income (loss) attributable to NCI, net of tax	53.9			(0.7		)	49.1			7.7
Fair value of net assets and liabilities acquired and assigned to NCI	0.2			—			0.1			4.0
Distribution to NCI	(60.0		)	—			(60.0		)	(9.1		)
Translation adjustment and other	(0.3		)	—			—			—
NCI, end of period	$	(5.8	)	$	3.2		$	(5.8	)	$	3.2

For the three and nine months ended September 30, 2015, net income (loss) attributable to NCI, net of tax, was related to a $60.0 million milestone payment made to Neurimmune SubOne AG. For additional information, please read Note 17, Investments in Variable Interest Entities, to these condensed consolidated financial statements.